Sanofi has told employees of Cambridge, Mass.-based Genzyme, the biotech Sanofi acquired in April, that they will have a new reporting structure within the parent company, according to The Boston Globe.

Sanofi CEO Christopher A. Viehbacher said earlier this year that Genzyme will retain its name and remain a standalone biotechnology unit within Sanofi.

But in an employee bulletin out this week, Sanofi said the Genzyme unit will be smaller and include only its personalized genetic health and multiple sclerosis operations.

Genzyme’s current oncology, biosurgery and renal operations will be integrated into Sanofi businesses, the bulletin said. It did not say if that move would involve job cuts. Genzyme currently employs about 4,500 in Massachusetts and 10,000 worldwide.

Sanofi said Viehbacher will continue as acting Genzyme CEO until September, when a new Genzyme CEO will be named.